Method for modulating metabolism

Abstract

A method for modulating metabolism is provided which includes the step of providing a consumable composition including an extract containing a compound of Formula I to a subject in need thereof thereby modulating the subject's metabolism and addressing the underlying pathogenesis of metabolic disorders, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and type II diabetes mellitus.

What is claimed is: 
     
         1 . A method for treating a metabolic disorder in a subject, the method comprising:
 orally administering to a subject in need thereof a consumable composition comprising at least one carrier and an effective amount of one or more compounds selected from the group consisting of: N-trans-caffeoyltyramine, N-cis-caffeoyltyramine, N-trans-feruloyltyramine, N-cis-feruloyltyramine, p-coumaroyltyramine, cinnamoyltyramine, sinapoyltyramine, and 5-hydroxyferuloyltyramine;
 wherein the compound comprises between 0.1% to 99% of the composition, thereby treating a metabolic disorder. 
   
     
     
         2 . The method of  claim 1 , wherein the one or more compounds is N-trans-caffeoyltyramine and N-trans-feruloyltyramine. 
     
     
         3 . The method of  claim 1 , wherein the consumable composition further comprises a preservative. 
     
     
         4 . The method of  claim 1 , wherein the preservative comprises 0.01% to 5% of the composition. 
     
     
         5 . The method of  claim 1 , wherein the composition if a powder. 
     
     
         6 . The method of  claim 1 , wherein the consumable composition is formulated as a liquid. 
     
     
         7 . The method of  claim 6 , wherein the liquid is selected from a syrup, suspension, or an emulsion. 
     
     
         8 . The method of  claim 1 , wherein the consumable composition is administered between 0.0001 mg to about 10 grams per kilograms of body weight per day. 
     
     
         9 . The method of  claim 1 , wherein the metabolic disorder is selected from insulin resistance, hyperglycemia, type II diabetes mellitus, obesity, fatty liver disease, glucose intolerance, hypercholesterolemia, hyperlipoproteinemia, dyslipidemia, hyperinsulinemia, atherosclerotic disease, coronary artery disease, metabolic syndrome, and hypertension 
     
     
         10 . The method of  claim 1 , wherein the metabolic disorder is selected from abnormal plasma lipoprotein and pancreatic beta regeneration. 
     
     
         11 . A method for modulating HNF4α in a subject, the method comprising:
 orally administering to a subject in need thereof a consumable composition comprising at least one carrier and an effective amount of one or more compounds selected from the group consisting of: N-trans-caffeoyltyramine, N-cis-caffeoyltyramine, N-trans-feruloyltyramine, N-cis-feruloyltyramine, p-coumaroyltyramine, cinnamoyltyramine, sinapoyltyramine, and 5-hydroxyferuloyltyramine; 
 wherein the compound comprises between 0.1% to 99% of the composition, 
 thereby modulating HNF4α in the subject. 
 
     
     
         12 . The method of  claim 11 , wherein the compound increases the change of insulin mRNA in the subject. 
     
     
         13 . The method of  claim 11 , wherein the compound increases the change of HNF4α mRNA in the subject. 
     
     
         14 . The method of  claim 11 , wherein the compound increases the HNF4α expression in the subject. 
     
     
         15 . The method of  claim 10 , wherein the compound increases nuclear expression of HNF4α in the liver in the subject. 
     
     
         16 . A method for treating obesity in a subject, the method comprising:
 orally administering to a subject in need thereof a consumable composition comprising at least one carrier and an effective amount of one or more compounds selected from the group consisting of: N-trans-caffeoyltyramine, N-cis-caffeoyltyramine, N-trans-feruloyltyramine, N-cis-feruloyltyramine, p-coumaroyltyramine, cinnamoyltyramine, sinapoyltyramine, and 5-hydroxyferuloyltyramine;   wherein the compound comprises between 0.1% to 99% of the composition,   thereby treating obesity in the subject.   
     
     
         17 . The method of  claim 16 , wherein the subject's triglyceride levels are reduced. 
     
     
         18 . The method of  claim 16 , wherein the subject's harmful liver fats are reduced. 
     
     
         19 . The method of  claim 16 , wherein the subject's lipid accumulation is reduced. 
     
     
         20 . The method of  claim 16 , wherein at least one of the subject's alkaline phosphatase (ALP), alanine transaminase (ALT), γ-glutamyltransferase (GGT), bilirubin, artresia, total albumin, albumin, blood urea nitrogen, and cholesterol is reduced.